Peptidylglycine alpha-amidating monooxygenase- and proadrenomedullin-derived peptide-associated neuroendocrine differentiation are induced by androgen deprivation in the neoplastic prostate by Jimenez, N. (Nuria) et al.
PEPTIDYLGLYCINE a-AMIDATING MONOOXYGENASE- AND
PROADRENOMEDULLIN-DERIVED PEPTIDE–ASSOCIATED NEUROENDOCRINE
DIFFERENTIATION ARE INDUCED BY ANDROGEN DEPRIVATION IN THE
NEOPLASTIC PROSTATE
Nuria JIME´NEZ1,* Johan JONGSMA2, Alfonso CALVO1, Theodorus H. VAN DER KWAST2, Anthony M. TRESTON3, Frank CUTTITTA3,
Fritz H. SCHRO¨DER2, Luis M. MONTUENGA1 and Gert J. VAN STEENBRUGGE2
1Department of Histology and Pathology, University of Navarra, Pamplona, Spain
2Department of Experimental Urology and Pathology, Josephine Nefkens Institute, Rotterdam, The Netherlands
3National Cancer Institute, National Institutes of Health, Rockville, MD, USA
Most PCs show NE differentiation. Several studies have
tried to correlate NE expression with disease status, but the
reported findings have been contradictory. Prostatic NE cells
synthesize peptides with a wide spectrum of potential func-
tions. Some of these active peptides, such as PAMP, are
amidated. PAM is the only carboxy-terminal peptide–amidat-
ing enzyme identified. We studied expression of PAMP and
PAM in normal prostate and prostatic tumors (clinical spec-
imens and human xenograft models) with or without prior
androgen-deprivation therapy and found a wide distribution
of both molecules in NE subpopulations of all kinds. Although
the correlation of either marker to tumor grade, clinical
progression or disease prognosis did not reach statistical
significance, PAMP- or PAM-immunoreactive cells were in-
duced after androgen-blockade therapy. In the PC-310 and
PC-295 androgen-dependent models, PAMP or PAM NE dif-
ferentiation was induced after castration in different ways,
being higher in PC-310, which might explain its long-term
survival after androgen deprivation. We show induction of
expression of 2 new NE markers in clinical specimens and
xenografted PC after endocrine therapy.
© 2001 Wiley-Liss, Inc.
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PC is the most commonly diagnosed cancer in elderly men1
and is becoming the leading malignant cause of death for men
in this age group. The normal prostatic epithelium has a well-
developed NE cell population.2 In PC, the reported incidence of
NE cells has increased as detection methods have improved.3,4
The function of the NE population in the normal and malignant
prostate remains unknown. Together with generic NE markers,
such as CgA or CgB,5 prostatic NE cells produce biogenic
amines and neuropeptides.6 The effects of some of these on
prostatic cells have been demonstrated in vitro in some in-
stances. Serotonin and bombesin/gastrin-releasing peptide act
as growth-stimulating factors,7 while somatostatin is a growth
inhibitor.8 Thus, NE cells could play a role in the regulation of
growth, differentiation and local homeostasis of the normal and
neoplastic prostate in vivo.
PAMP and AM originate from the posttranslational processing
of pro-AM.9,10 PAMP, but not AM, was specifically expressed by
some NE cells of the human normal prostate.11 NE expression in
other tissues has also been associated with PAMP production.12
However, this peptide was first described in the vascular wall and
in endocrine organs in normal and pathologic situations.13 PAMP
is a pluripotent peptide initially identified as a vasodilator,9 but it
can additionally act as a neural transmission inhibitor,14 an endo-
crine secretion inhibitor15 or a cell growth suppressor.16 Some of
these roles could contribute to the regulation of prostatic ho-
meostasis or functioning.
Some peptides produced by prostatic NE cells (PAMP, gastrin-
releasing peptide and calcitonin) are carboxy-terminally amidated
in vivo.13,17 C-terminal a-amidation is a posttranslational modifi-
cation necessary for many peptides to be completely bioactive.17 It
is sequentially performed by PHM and peptidyl-a-hydroxyglycine
a-amidating lyase,18 which are included in the PAM precursor.
PAM has been detected in endocrine and other tissues in both
normal and neoplastic states.19,20 PAM mRNA has been detected
in rat prostate and human prostatic xenografts.21,22 Although PAM
is expressed by many NE cells, this enzyme cannot be considered
a general NE marker as it is not present in every cell from the
diffuse NE system.23
PC is androgen-dependent in early stages but usually relapses to
an androgen-insensitive state after androgen-withdrawal therapy,24
which implies more aggressive tumors and a poor prognosis for the
patient. Since prostatic NE cells lack androgen receptors, they
have been suggested to be androgen-independent25 and, therefore,
assumed to be involved in the development of refractory tumors.
However, several studies on the relationship of NE differentiation
(usually represented by universal NE markers) to prognosis in PC
have reported contradictory findings.26 In the present study, we
describe PAMP and PAM expression in NE cells of human pros-
tatic specimens obtained from a broad spectrum of histopathologic
subgroups. Our aim was to use these 2 new NE markers to gain
insight into the relevance of single NE subpopulations producing
specific products (with potential effects on tumor biology) on the
evolution of prostatic tumors either untreated or pretreated with
androgen-deprivation therapy.
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MATERIAL AND METHODS
Patients
Two control prostates were obtained from autopsies of healthy
young individuals killed in traffic accidents. Neoplastic tissues
were obtained by RP over 10 years at the University Hospital
Rotterdam (The Netherlands) or through TURPs mainly performed
at the University Hospital Rotterdam and the Reinier de Graaff
Hospital (Delft, The Netherlands). RPs were performed on 61
patients with nonmetastasized, clinically localized or locally ad-
vanced PC. Patients were followed regularly for a mean period of
82 months (range 13–178). Clinical progression, defined as cyto-
logically or histologically proven local recurrence or the appear-
ance of distant metastasis, occurred in 27 patients. Tumor-specific
death, defined as death due to direct tumor effects, metastasis or
tumor therapy, occurred in 11/27 patients showing disease pro-
gression. TURPs were obtained from 29 patients with extensive
tumors. Fourteen of them were pretreated with androgen-blockade
therapy, i.e., by antiandrogens, flutamide, androcur or orchiectomy
(P-TURPs). The rest (n 5 15) were untreated before undergoing
surgery (U-TURPs). All tissue-procurement protocols were ap-
proved by the relevant institutional committees. Prostates were
fixed in 10% buffered formalin, dehydrated in alcohol and embed-
ded in paraffin for in situ detection. Slides stained with hematox-
ylin and eosin were used for determining tumor grade according to
GSS.
Human prostate tumor xenograft models
PC-295 and PC-310 models were established, respectively, from
a pelvic lymph node metastasis and from a primary PC at the
Department of Experimental Urology, Erasmus University (Rot-
terdam, The Netherlands).27 These androgen-dependent models
exhibit significantly increased NE differentiation after androgen
ablation.21,22 Small pieces of tumor were heterotransplanted in
NMRI athymic nude mice by s.c. implantation. Mice (Harlan,
Indianapolis, IN) were androgen-supplemented through silicone
(Silastic) implants containing testosterone (Sigma, St. Louis, MO).
Tumors were grown to a maximal volume of 2,000 mm.3 For
castration experiments, implants were removed and male mice
castrated under Hypnorm anesthesia (Janssen, Oxford, UK). Mice
were killed at short-term intervals after androgen ablation: days 0,
0.5, 1, 1.5, 2, 4, 7, 14 and 21 for PC-295 and days 0, 2, 5, 7, 14 and
21 for PC-310. A long-term castration experiment was also per-
formed for PC-310, mice being killed 0, 21, 47, 84, 90 and 154
days after androgen withdrawal. Prostatic tumors were then either
fixed in 4% buffered formalin and paraffin-embedded for immu-
nohistochemic detection or snap-frozen in liquid nitrogen and
stored at –80°C for Western blotting.
We included other models,27,28 both androgen-dependent and
-independent, also established at the Department of Experimental
Urology: PC-82, PC-133, PC-135, PC-324, PC-329, PC-339, PC-
346, PC-346I and PC-374. All tumors were grown in mice as
described above. Mice were killed at 0 and 14 days after androgen
withdrawal (though these models did not exhibit NE differentia-
tion after androgen withdrawal previously29). Tissues were pro-
cessed for immunohistochemic analysis.
Antibodies and peptides
For PAMP detection, a previously characterized30 polyclonal
antiserum (raised to the C-terminal PAMPYY13-20AMIDE peptide)
was applied at 1:3,000 on histologic sections and at 1:1,500 for
Western blotting. This antibody does not cross-react with other
carboxy-terminally amidated peptides, including AM.30 To detect
PHM and PAM, 2 monoclonal antisera (clones G8 and E10,
produced by Dr. A.M. Treston, NCI, NIH, Bethesda, MD) were
used. They were raised against bovine PHM (bPAM288-310; Gen-
bank accession M18683), which shows high homology with the
human PAM288-310 sequence. Both antibodies were applied at
1:2,000 on sections of clinical material and at 1:1,000 on sections
of xenograft-derived tissues. A monoclonal antihuman CgA anti-
serum (Boehringer-Mannheim, Mannheim, Germany) was applied
at 2 mg/ml to confirm whether PAMP- and PAM-expressing cells
had the NE phenotype. Peptides PAMPYY13-20AMIDE and
bPAM288-310 were used for the absorption controls.
Immunohistochemistry
Sections (4 mm thick) were cut from paraffin-embedded tissues
and placed on slides. Some reverse-face sections were mounted to
assess colocalization of molecules. To detect PAMP, PAM and
CgA single immunostaining, a previously described protocol was
used.21 For absorption controls, solutions containing the specific
antiserum preincubated with 10 nmol/ml of its respective peptide
overnight at 4°C were applied to slides instead of primary anti-
serum.
For double immunodetection, sections were deparaffinized and
hydrated and endogenous peroxidase was inhibited. Next, they
were microwave-preheated as previously described.21 Slides were
then incubated for 20 min with normal goat serum (1:20) at room
temperature and at 4°C overnight with the specific antiserum
mixture (containing 1 monoclonal and 1 polyclonal antiserum).
Subsequently, slides were treated with horseradish peroxidase–
conjugated goat antirabbit immunoglobulins and with unlabeled
goat antimouse immunoglobulins (Dako, Copenhagen, Denmark),
diluted 1:50 and 1:100, respectively, for 30 min. Tissues were
incubated with monoclonal APAAP (Dako) at 1:50 for 30 min.
Goat antimouse antiserum was applied again, followed by
APAAP, for 10 min each. Alkaline phosphatase was developed
using naphthol AS-TR and new fuchsin as substrate to give a red
end product. Peroxidase activity was detected with 3,39-diamino-
benzidine hydrochloride and nickel enhancement, rendering a
black precipitate. Slides were embedded in PBS-glycerol.
Quantification of immunostaining and statistical analysis of data
For RPs and TURPs, NE cells immunolabeled for PAMP or
PAM were evaluated semiquantitatively since this allowed us to
consider the distribution pattern (regular or irregular) of positive
cells throughout the tissue.31 Tissue sections adjacent to slides
immunostained for PAMP or PAM were stained with hematoxylin
and eosin and the neoplastic zones present in every tissue identi-
fied and marked. These marks were copied on the corresponding
immunolabeled slides. For scoring, we used a microscope
equipped with an ocular with an integrated grid of 9 mm along
each side. The grid area defined a field. Ten fields of tumor tissue
were randomly selected at 3160, and cells showing granular
cytoplasmatic immunostaining were counted. The presence of cell
clusters was recorded. The total area scored was 0.03 mm.2 Quan-
titative data were transformed to semiquantitative values, which
consider not only the observed number but also the distribution of
positive cells. The final scoring criteria were as follows: 0, no
positive cells; 1, positive cells in 4 or fewer fields; 2, positive cells
in at least 5 fields; 3, more than 6 positive cells in at least 5 fields
or clusters of 10 or more positive cells in at least 1 field. Therefore,
every tumor was assigned 1 semiquantitative score (0–3) for
PAMP and another for PAM.
In the xenograft models, quantitative evaluation of PAMP ex-
pression was performed to determine how immunoreactive cells
evolved after castration. Ten randomly selected fields of neoplastic
epithelium were scored at 3400 by counting the positive cells. The
arithmetic mean calculated from the 10 data points was assigned as
final value for each tumor. The mean area analyzed was 500 mm.2
SPSS (Chicago, IL) software was used for statistical analysis.
The PAMP or PAM score of each patient was correlated to the
respective GSS. The PAMP score was correlated to the PAM
score. The means calculated for the xenograft models were corre-
lated with postcastration time. To carry out correlation analysis,
the nonparametric Spearman coefficient (r) was determined.
Scores from patients who underwent RP were also related to
clinical progression and survival time (Kaplan-Meier method). The
frequency of high PAMP or PAM NE expression (score 3) in
U-TURPs and P-TURPs was compared by Fisher’s exact test.
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Protein extraction and Western blotting
PC-310 prostatic tissues stored at –80°C were crushed in a
metal cylinder cooled to –80°C. Tissue homogenates were trans-
ferred into a lysis buffer21 containing a cocktail of protease inhib-
itors (Complete, Boehringer-Mannheim). After centrifugation of
the mixture at 40,000g at 4°C for 10 min, supernatants were
recovered and the protein content was measured spectrophoto-
metrically by the Bradford method (protein assay from Bio-Rad,
Munich, Germany).
For Western blotting detection of PAMP, each sample (35 mg)
was transferred to 10–20% tricine SDS-PAGE gels (Novex, San
Diego, CA). Synthetic PAMP (5 ng) was loaded in separate wells
as a positive control. Unstained Mark12 Wide Range Protein
Standard (Novex) was loaded to determine relative m.w. Proteins
were electrophoretically separated under reducing conditions. Gels
were blotted to PVDF membranes (Immobilon; Millipore, Bed-
ford, MA). The immunoblot was blocked overnight at 4°C with
PBS (pH 7.7) containing 5% dry milk. Anti-PAMP antiserum
diluted in PBS/milk was added subsequently, and the membranes
were incubated for 1 hr on an orbital shaker at room temperature.
After rinsing membranes with PBS containing 0.1% Tween-20
(Fluka, Buchs, Switzerland), incubation with horseradish peroxi-
dase–conjugated antirabbit secondary antibody (Amersham, Ay-
lesbury, UK) diluted 1:5,000 in PBS/milk was performed for 1 hr
at room temperature. Membranes were rinsed with PBS/Tween,
and Western blotting luminol reagent (Santa Cruz Biotechnology,
Santa Cruz, CA) was added for 1 min. Blots were then exposed to
high-performance chemiluminescence film (Hyperfilm ECL, Am-
ersham). Finally, blots were stained with Serva Blue R (Serva
Electrophoresis, Heidelberg, Germany) following the manufactur-
er’s instructions, to visualize protein standards.
RESULTS
Immunodetection and quantification of PAMP and PAM in
clinical specimens
PAMP-like and PAM-like immunostaining, granular and cyto-
plasmatic, was detected in normal and neoplastic prostates (Fig.
1a–d). PAMP- or PAM-immunoreactive cells were mainly iso-
lated in the epithelium of ducts and acini in the normal glands (Fig.
1a,b) and other prostate-associated structures, such as the utriculus
and the urethra. In the neoplastic glands, positive cells were
distributed as either isolated or clustered cells (Fig. 1c,d). Double
immunostaining and serial reverse-face staining demonstrated that
both PAMP1 and PAM1 cells showed the NE phenotype as they
were subpopulations of CgA1 cells (data not shown). Absorption
controls confirmed the specificity of staining (Fig. 1e).
FIGURE 1 – NE PAM-like (a,c) and PAMP-like (b,d) expression and PAM absorption control (e). (a,b) Normal prostate. (c,e) P-TURP, GSS
10, serial sections. (d) RP, GSS 8. Inset, PAMP cytoplasmatic and granular expression. (c,e) Arrows point to the same blood vessel. Nuclei
appear stained by the counterstaining (Mayer’s hematoxylin). Scale bar 5 100 mm; inset 3500.
30 JIME´ NEZ ET AL.
NE PAMP-like expression was detected in 80% of RPs, 80% of
U-TURPs and 79% of P-TURPs. PAMP scores in relation to GSS
are shown in Tables I and II. There was no correlation between
PAMP score and GSS for the RPs (r 5 –0.012, p . 0.05) or the
U-TURPs (r 5 –0.078, p . 0.05). However, P-TURPs showed a
positive correlation between scores (r 5 0.489), though it did not
reach statistical significance (p 5 0.076). To score PAM-express-
ing NE cells, the anti-PHM antiserum clone G8 (which is more
sensitive than antibody clone E10) was used. NE-associated PAM
expression was present in 46% of RPs, 27% of U-TURPs and 36%
of P-TURPs (Tables I, II). Spearman’s coefficient indicated no
correlation between GSS and PAM score for the RPs (r 5 0.070,
p . 0.05). The correlation coefficient was negative for U-TURPs
(r 5 –0.302, p . 0.05) and positive for P-TURPs (r 5 0.347, p .
0.05). There was a noticeable increase in the percentage of patients
expressing high PAMP (score 3) from untreated (1/15, 7%) to
pretreated (5/14, 36%) TURPs (p 5 0.08, n 5 29); 27% of
P-TURPs and 7% of U-TURPs exhibited high PAM expression,
but these percentages were not significantly different (p 5 0.169).
Kaplan-Meier curves did not show a prognostic value of PAMP or
PAM expression in relation to clinical progression or tumor-
specific survival of the RPs (data not shown).
Colocalization of PAM and PAMP immunoreactivity revealed 3
types of NE cell: cells positive only for PAM, cells immunolabeled
only for PAMP and cells immunostained for both PAMP and
PAM. To assess whether the relationship between PAM and
PAMP expression exists, the correlation between both scores was
calculated. For the RPs, there was a positive and significant cor-
relation (r 5 0.494, p , 0.001). For the TURPs, the correlation
was smaller and not significant (r 5 0.208 for U-TURPs and 0.307
for P-TURPs).
Immunodetection and quantification of PAMP and PAM in
xenograft models
PAMP-like immunoreactive cells showed a marked increase in
the PC-310 model with postcastration time (Table III). At 7 days
postcastration (T-7), positive cells increased mainly in the periph-
eral area of the tumor; in time, they became numerous in the tumor
central zone after androgen deprivation (Fig. 2a). In the short-term
castration experiment done with the PC-295 model, PAMP-asso-
ciated NE differentiation was lower. The first PAMP cells were
detected at T-7, and the maximum number of positive cells (mean
0.9 6 SEM) was observed at T-14. There was a positive and
significant correlation between postcastration time and the number
of PAMP-immunostained cells for PC-310 (r 5 0.976, p , 0.001)
and PC-295 (r 5 0.822, p 5 0.007). Both models showed induc-
tion of CgA-expressing cells after androgen deprivation. CgA1
cells were found at low levels at T-0 but increased in tumor areas
from the peripheral to the central zone after longer periods of
androgen deprivation (Fig. 2b). PAMP1 cells were a subpopula-
tion of prostatic CgA-expressing cells (Fig. 2a,b). In both models,
CgA cells showed a trend to be the main tumor cell type at later
stages in the postcastration period. This was also observed for the
PAMP1 subpopulation in PC-310 but not in PC-295.
Labeling for PAM, usually strong and granular, was localized in
some epithelial cells later assessed as NE in the PC-310 and
PC-295 models. Faint, diffuse PAM staining was also found in the
non-NE neoplastic epithelium. NE-associated PAM expression
colocalized not only with CgA- but also with PAMP-expressing
NE cells (Fig. 2a–c). In the PC-310 model, PAM1 NE cells
appeared relatively late postcastration (i.e., T-21). The increase in
PAM NE differentiation appeared later after androgen deprivation
than PAMP differentiation as the positive cells became numerous
from T-84 on. The PC-295 model showed a slight increase in
PAM-expressing NE cells following androgen ablation. PAM NE
cells were not counted because the parallel increased staining of
non-NE tumor cells made the scoring unreliable.
Most of the other xenograft models studied did not exhibit PAMP
immunolabeling. Some sporadic immunostained cells were observed
at T-14 in the androgen-dependent PC-82 and PC-329 models and in
the androgen-independent PC-374 model. Tumor epithelia in the
androgen-dependent PC-82, PC-329 and PC-346 models showed
weak epithelial PAM expression, which was stronger in the androgen-
independent PC-133, PC-135, PC-324, PC-339 and PC-374 xeno-
grafts. The androgen-independent subline PC-346I, derived from the
parental androgen-dependent PC-346 xenograft, exhibited areas with
strong epithelial staining surrounded by areas with low PAM expres-
sion. In the parental line as well as the subline of this model, overall
PAM expression increased after 14 days of androgen deprivation. In
every case, PAM-stained cells were assessed as non-NE, i.e., CgA–,
tumor cells.
TABLE I – RELATIONSHIP BETWEEN PAMP OR PAM SCORE AND GSS IN
RP (N 5 61)
Tumor
score
GSS
Total
4 5 6 7 8 9 10
0
PAMP 0 1 1 4 3 3 0 12
PAM 1 2 5 12 6 5 2 33
1
PAMP 1 1 7 13 3 7 2 34
PAM 1 1 3 9 2 6 0 22
2
PAMP 1 0 0 3 0 0 0 4
PAM 0 0 0 1 0 1 0 2
3
PAMP 0 1 0 4 3 3 0 11
PAM 0 0 0 2 1 1 0 4
Total
PAMP 2 3 8 24 9 13 2 61
PAM 2 3 8 24 9 13 2 61
TABLE II – RELATIONSHIP BETWEEN PAMP OR PAM SCORE AND GSS IN
THE TURPS (N 5 29)
Tumor
score
Pretreated patients Untreated patients
GSS
Total
GSS
Total
7 8 9 10 7 8 9 10
0
PAMP 1 2 0 0 3 0 0 2 1 3
PAM 2 4 3 0 9 1 1 3 6 11
1
PAMP 1 2 3 0 6 1 1 4 5 11
PAM 0 0 1 0 1 0 0 3 0 3
2
PAMP 0 0 0 0 0 0 0 0 0 0
PAM 0 0 0 0 0 0 0 0 0 0
3
PAMP 0 2 2 1 5 0 0 1 0 1
PAM 0 2 1 1 4 0 0 1 0 1
Total
PAMP 2 6 5 1 14 1 1 7 6 15
PAM 2 6 5 1 14 1 1 7 6 15
TABLE III – TIME COURSE OF THE PRESENCE OF PAMP-LIKE POSITIVE
CELLS IN ANDROGEN-DEPRIVATION EXPERIMENTS USING THE PC-310
PROSTATE XENOGRAFT MODEL
Postcastration time
(days)
PAMP cells
(mean value) SEM
0 0.0 0.0
2 0.2 0.1
5 0.6 0.3
7 5.8 1.2
14 12.5 2.9
21 10.3 2.6
47 24.4 3.8
84 19.7 2.7
90 35.0 5.8
154 42.7 5.9
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PAMP Western blotting
The PC-310 model was studied with proteins from short- and
long-term experiments (Fig. 3). The 3 kDa band, corresponding
to fully processed PAMP, was not detectable in any of the
extracts. However, some larger bands (14 to 22 kDa) were
observed from T-21. The intensity of the signal increased with
androgen deprivation time, especially for species corresponding
to 15 and 14 kDa bands, which became stronger from T-21 to
T-84, though they were weaker at T-154 (Fig. 3b). In the
absorption controls, no signal was detected (data not shown).
PHM/PAM quantification by Western blot analysis was not
possible in PC-310 due to the strong background derived from
the mouse immunoglobulins present in the extracts, which were
recognized by our detection system.
DISCUSSION
The generalized presence of NE cells in PC and the androgen-
independent behavior of this cell type25 have suggested that the
prostatic NE population may be involved in the progression of cancer
and in the development of refractory tumors after endocrine therapy.
The contradictory conclusions on the relevance of NE cells in PC
reported by several groups26 encourage studies of the relation between
the expression of newly discovered prostatic NE products and PC
progression. We have studied the expression of 2 new NE markers
with potential roles in tumor biology (PAMP and PAM) in normal
prostate and prostatic tumors (both clinical and experimental) with
and without prior androgen-deprivation treatment.
Immunohistochemic analysis showed PAMP- and PAM-immuno-
reactive cells distributed with patterns similar to other NE markers in
the normal32 and malignant6 prostate. Both types of immunoreactive
cell are subpopulations of NE CgA-expressing cells. Therefore, our
findings in prostate and the data obtained from other systems23 dem-
onstrate that neither PAMP nor PAM is a general NE marker. The
incidence of NE differentiation in PC is variable depending on the NE
marker considered.3,33 The existence of NE subpopulations producing
specific substances is interesting since the secreted products could
potentially have different effects on neighboring non-NE tumor cells.
In the clinical material, we observed PAMP-like expression in 80% of
tumors while PAM was present to a lesser extent. PAM- and PAMP-
like signals colocalized in several NE cells, pointing to PAM, the only
amidating enzyme identified, as the candidate for PAMP amidation.
The absence of PAM in some PAMP-expressing cells might reflect
the accumulation of PAMP in cells requiring late coexpression of
PAM.
In accordance with observations made for other markers,31 we
did not find a correlation between PAM or PAMP expression and
GSS for either group of RPs or the TURPs. PAMP- or PAM-
associated NE differentiation does not appear to be directly asso-
ciated with tumor grade and, furthermore, does not have clinical
value for estimating prognosis. However, we found high PAMP
and PAM scores more frequently in palliative TURPs (PAMP
36%, PAM 27%) than in untreated TURPs (7% for both markers),
PAMP incidences being almost significantly different. This points
out that at least PAMP-immunoreactive NE cell differentiation
and/or selection is induced in hormone-refractory tumors after
antiandrogen therapy.
The xenograft models studied were heterogeneous with respect to
the presence and evolution of NE subpopulations after castration. This
can be related to the variability found in the clinical specimens as well
as each of the models originated from a different patient. During
androgen-deprivation experiments, the PC-295 and PC-310 models
exhibited tumor regression21,22 but PC-310 tumors survived as dor-
mant residues for at least 5 months. PC-295 tumor epithelium re-
gressed completely in a short period after androgen ablation. In both
models, CgA1 cells become the main epithelial cell type after pro-
longed androgen withdrawal. In the present study, PAM- or PAMP-
associated NE differentiation was induced in 2 different ways: in
PC-310, PAMP cells increased sharply in parallel to the increase of
CgA1 cells and high PAM NE differentiation was induced (relatively
late); in PC-295, the number of PAMP1 or PAM1 cells induced was
limited. The differences in survival time after hormone deprivation in
both models could be related to the different patterns of induction of
FIGURE 2 – Immunoreactivity in a tumor epithelial node of the
PC-310 model at T-90 for PAMP (a), CgA (b) and PAM (c). More
stained PAM cells are situated in coincident zones with the cells
immunoreactive for CgA and PAMP. Counterstaining by Mayer’s
hematoxylin. Scale bar 5 100 mm.
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NE subpopulations. For the PC-310 model, NE products could act as
alternative growth factors, promote survival of dormant tumors or
exert a vasodilatory effect on mouse stromal vessels in the xenograft
after androgen depletion.
Immunohistochemic studies in organs such as normal prostate
and pituitary have concluded that PAMP and AM do not always
colocalize in the same cells,11,34 though they are processed from
the common precursor pro-AM. In Western blot analysis for PC-
310–derived material, we did not detect fully processed PAMP.
This may indicate that the PAMP-immunoreactive molecule pro-
duced by the PC-310 model is not fully active or that the mature
peptide is present below the detection threshold of the technique.
The latter possibility could be due to regulation of the final steps
of protein processing, resulting in a slow rate of PAMP production
or fast secretion and/or degradation of mature PAMP. The immu-
noreactive bands we found (14–22 kDa) may correspond to the
previously reported precursor form and processing-derived pep-
tides or even to species related to the pro-AM alternatively spliced
mRNA.35 In any case, the intensity of the bands corresponding to
PAMP-related molecules (especially the 14 kDa peptide) increased
as postcastration time advanced. The diminished intensity ob-
served at T-154 is very likely due to the increase of mouse stromal
protein relative volume present at this time point.
Expression of PAMP and PAM was related to androgen-insensitive
human NE cells. The postcastration increase of immunoreactivity for
PAMP observed by Western blotting and immunohistochemistry in
the PC-310 model and the detection of PAMP-like expressing cells in
clinical specimens after androgen-ablation therapy are in apparent
contrast to another report of downregulation of pro-AM gene expres-
sion after castration.36 In that report, the mRNA encoding the tradi-
tional pro-AM in the ventral lobe of the rat prostate was analyzed. Rat
prostate is a very complex organ composed of ventral, lateral and
dorsal lobes, which differ from each other. The dorsal, but not the
ventral, rat prostate is embryologically close to the human organ. In
the rat, the epithelial cells of every lobe are androgen-dependent but
some genes, such as the one encoding for C-CAM epithelial cell-
adhesion molecule, are distinctly regulated in the dorsal or lateral
lobes with respect to the ventral ones after castration.37 Thus, regu-
lation by androgens of pro-AM gene expression or its alternative
splicing may be different in the rat prostatic ventral lobe compared to
the human prostate.
In summary, NE differentiation of PC cells producing PAMP-
related peptides, and PAM is induced by androgen deprivation in
2 xenograft models and in tumors from patients pretreated with
androgen blockade, showing the similarity between the experimen-
tal and the clinical settings. Our results implicate specific NE
subpopulations in the progression of the disease after antiandrogen
therapy. Despite the variability between individuals, further exper-
iments to determine the putative effect of NE products on the
evolution of PC are necessary to determine if the concept should
be considered when new treatment strategies for hormone-refrac-
tory prostatic tumors are developed.
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